BCL-2 Inhibitor Receives Accelerated Approval Following Phase 1/2 Study

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Beqalzi™ (sonrotoclax), a next-generation BCL-2 inhibitor developed by BeOne Medicines, for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL) in patients who have received prior Bruton’s tyrosine kinase (BTK) inhibitor therapy. The approval marks the first FDA nod for a BCL-2 inhibitor specifically targeting this patient population, addressing a critical area of unmet need in oncology.

The decision follows data from the Phase 1/2 clinical trial BGB-11417-201 (NCT05471843), which demonstrated meaningful efficacy in heavily pretreated patients. The trial, presented at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, showed an overall response rate (ORR) of 52.4% and a complete response (CR) rate of 15.5% among 103 participants. Responses were observed as early as 1.9 months on treatment, with a median follow-up of 14.2 months.

Mantle cell lymphoma is an aggressive form of non-Hodgkin lymphoma, and patients who progress after BTK inhibitor therapy—such as those treated with ibrutinib or acalabrutinib—have limited salvage options. The approval of Beqalzi introduces a novel mechanism of action, targeting the BCL-2 protein to restore intrinsic apoptosis in cancer cells by displacing pro-apoptotic proteins. This approach differs from existing BCL-2 inhibitors like venetoclax (Venclexta), which are approved for other hematologic malignancies but not for R/R MCL in this context.

BeOne Medicines’ submission highlighted the drug’s safety profile and tolerability in the Phase 1/2 trial, though long-term data and comparative effectiveness against existing therapies remain areas of ongoing investigation. The FDA’s accelerated approval pathway allows for earlier patient access based on surrogate endpoints, with a requirement for confirmatory trials to verify clinical benefit.

This approval comes as part of a broader push to expand treatment options for rare and aggressive lymphomas. Beqalzi’s launch positions BeOne Medicines as a competitor in the BCL-2 inhibitor space, where venetoclax (AbbVie) currently dominates. Analysts suggest the drug could carve out a niche for patients who have exhausted other targeted therapies, though real-world adoption will depend on pricing, insurance coverage, and comparative efficacy data.

For patients with R/R MCL, the approval offers a new therapeutic avenue, though clinicians emphasize the importance of individualized treatment plans. The FDA’s decision underscores the agency’s commitment to advancing precision oncology, particularly for diseases with limited standard-of-care options.

BeOne Medicines has not yet disclosed a commercial launch date for Beqalzi in the U.S., but the company has indicated plans to pursue global regulatory submissions in the coming months. Updates on confirmatory trial results and post-marketing studies will be critical in determining the drug’s long-term role in MCL treatment paradigms.